These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24754609)

  • 1. Structural basis for isoform selectivity in a class of benzothiazole inhibitors of phosphoinositide 3-kinase γ.
    Collier PN; Martinez-Botella G; Cornebise M; Cottrell KM; Doran JD; Griffith JP; Mahajan S; Maltais F; Moody CS; Huck EP; Wang T; Aronov AM
    J Med Chem; 2015 Jan; 58(1):517-21. PubMed ID: 24754609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insight into the selective mechanism of phosphoinositide 3-kinase γ with benzothiazole and thiazolopiperidine γ-specific inhibitors by in silico approaches.
    Zhu J; Li K; Xu L; Jin J
    Chem Biol Drug Des; 2019 May; 93(5):818-831. PubMed ID: 30582283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Highly Isoform Selective Thiazolopiperidine Inhibitors of Phosphoinositide 3-Kinase γ.
    Collier PN; Messersmith D; Le Tiran A; Bandarage UK; Boucher C; Come J; Cottrell KM; Damagnez V; Doran JD; Griffith JP; Khare-Pandit S; Krueger EB; Ledeboer MW; Ledford B; Liao Y; Mahajan S; Moody CS; Roday S; Wang T; Xu J; Aronov AM
    J Med Chem; 2015 Jul; 58(14):5684-8. PubMed ID: 26121481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and optimization of a series of 2-aminothiazole-oxazoles as potent phosphoinositide 3-kinase γ inhibitors.
    Oka Y; Yabuuchi T; Fujii Y; Ohtake H; Wakahara S; Matsumoto K; Endo M; Tamura Y; Sekiguchi Y
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7534-8. PubMed ID: 23122859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of N-{5-[3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl]-4-methyl-1,3-thiazol-2-yl}acetamide (TASP0415914) as an orally potent phosphoinositide 3-kinase γ inhibitor for the treatment of inflammatory diseases.
    Oka Y; Yabuuchi T; Oi T; Kuroda S; Fujii Y; Ohtake H; Inoue T; Wakahara S; Kimura K; Fujita K; Endo M; Taguchi K; Sekiguchi Y
    Bioorg Med Chem; 2013 Dec; 21(24):7578-83. PubMed ID: 24262886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
    Pomel V; Klicic J; Covini D; Church DD; Shaw JP; Roulin K; Burgat-Charvillon F; Valognes D; Camps M; Chabert C; Gillieron C; Françon B; Perrin D; Leroy D; Gretener D; Nichols A; Vitte PA; Carboni S; Rommel C; Schwarz MK; Rückle T
    J Med Chem; 2006 Jun; 49(13):3857-71. PubMed ID: 16789742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors.
    Wang X; Sarris K; Kage K; Zhang D; Brown SP; Kolasa T; Surowy C; El Kouhen OF; Muchmore SW; Brioni JD; Stewart AO
    J Med Chem; 2009 Jan; 52(1):170-80. PubMed ID: 19072118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Class I phospho-inositide-3-kinases (PI3Ks) isoform-specific inhibition study by the combination of docking and molecular dynamics simulation.
    Han M; Zhang JZ
    J Chem Inf Model; 2010 Jan; 50(1):136-45. PubMed ID: 19928754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SAR studies around a series of triazolopyridines as potent and selective PI3Kγ inhibitors.
    Bell K; Sunose M; Ellard K; Cansfield A; Taylor J; Miller W; Ramsden N; Bergamini G; Neubauer G
    Bioorg Med Chem Lett; 2012 Aug; 22(16):5257-63. PubMed ID: 22819766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform.
    Heffron TP; Wei B; Olivero A; Staben ST; Tsui V; Do S; Dotson J; Folkes AJ; Goldsmith P; Goldsmith R; Gunzner J; Lesnick J; Lewis C; Mathieu S; Nonomiya J; Shuttleworth S; Sutherlin DP; Wan NC; Wang S; Wiesmann C; Zhu BY
    J Med Chem; 2011 Nov; 54(22):7815-33. PubMed ID: 21985639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting phosphatidylinositol 3-kinase gamma (PI3Kγ): Discovery and development of its selective inhibitors.
    Zhu J; Li K; Yu L; Chen Y; Cai Y; Jin J; Hou T
    Med Res Rev; 2021 May; 41(3):1599-1621. PubMed ID: 33300614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase γ (PI3Kγ) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS).
    Come JH; Collier PN; Henderson JA; Pierce AC; Davies RJ; Le Tiran A; O'Dowd H; Bandarage UK; Cao J; Deininger D; Grey R; Krueger EB; Lowe DB; Liang J; Liao Y; Messersmith D; Nanthakumar S; Sizensky E; Wang J; Xu J; Chin EY; Damagnez V; Doran JD; Dworakowski W; Griffith JP; Jacobs MD; Khare-Pandit S; Mahajan S; Moody CS; Aronov AM
    J Med Chem; 2018 Jun; 61(12):5245-5256. PubMed ID: 29847724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases.
    Cushing TD; Metz DP; Whittington DA; McGee LR
    J Med Chem; 2012 Oct; 55(20):8559-81. PubMed ID: 22924688
    [No Abstract]   [Full Text] [Related]  

  • 14. A class of highly selective inhibitors bind to an active state of PI3Kγ.
    Gangadhara G; Dahl G; Bohnacker T; Rae R; Gunnarsson J; Blaho S; Öster L; Lindmark H; Karabelas K; Pemberton N; Tyrchan C; Mogemark M; Wymann MP; Williams RL; Perry MWD; Papavoine T; Petersen J
    Nat Chem Biol; 2019 Apr; 15(4):348-357. PubMed ID: 30718815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Potent and Selective PI3Kγ Inhibitors.
    Drew SL; Thomas-Tran R; Beatty JW; Fournier J; Lawson KV; Miles DH; Mata G; Sharif EU; Yan X; Mailyan AK; Ginn E; Chen J; Wong K; Soni D; Dhanota P; Chen PY; Shaqfeh SG; Meleza C; Pham AT; Chen A; Zhao X; Banuelos J; Jin L; Schindler U; Walters MJ; Young SW; Walker NP; Leleti MR; Powers JP; Jeffrey JL
    J Med Chem; 2020 Oct; 63(19):11235-11257. PubMed ID: 32865410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors for the treatment of inflammation and autoimmune disease.
    Venable JD; Ameriks MK; Blevitt JM; Thurmond RL; Fung-Leung WP
    Recent Pat Inflamm Allergy Drug Discov; 2010 Jan; 4(1):1-15. PubMed ID: 20017720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors.
    Leahy JW; Buhr CA; Johnson HW; Kim BG; Baik T; Cannoy J; Forsyth TP; Jeong JW; Lee MS; Ma S; Noson K; Wang L; Williams M; Nuss JM; Brooks E; Foster P; Goon L; Heald N; Holst C; Jaeger C; Lam S; Lougheed J; Nguyen L; Plonowski A; Song J; Stout T; Wu X; Yakes MF; Yu P; Zhang W; Lamb P; Raeber O
    J Med Chem; 2012 Jun; 55(11):5467-82. PubMed ID: 22548342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Action mechanisms and structure-activity relationships of PI3Kgamma inhibitors on the enzyme: a molecular modeling study.
    Kuang RR; Qian F; Li Z; Wei DZ; Tang Y
    Eur J Med Chem; 2006 Apr; 41(4):558-65. PubMed ID: 16545498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zopolrestat as a human glyoxalase I inhibitor and its structural basis.
    Zhai J; Zhang H; Zhang L; Zhao Y; Chen S; Chen Y; Peng X; Li Q; Yuan M; Hu X
    ChemMedChem; 2013 Sep; 8(9):1462-4. PubMed ID: 23857942
    [No Abstract]   [Full Text] [Related]  

  • 20. Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK).
    MacKinnon CH; Lau K; Burch JD; Chen Y; Dines J; Ding X; Eigenbrot C; Heifetz A; Jaochico A; Johnson A; Kraemer J; Kruger S; Krülle TM; Liimatta M; Ly J; Maghames R; Montalbetti CA; Ortwine DF; Pérez-Fuertes Y; Shia S; Stein DB; Trani G; Vaidya DG; Wang X; Bromidge SM; Wu LC; Pei Z
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6331-5. PubMed ID: 24138940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.